Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis - PubMed (original) (raw)

Meta-Analysis

. 2010 Jun 12;375(9731):2073-81.

doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.

Collaborators, Affiliations

Meta-Analysis

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

Chronic Kidney Disease Prognosis Consortium et al. Lancet. 2010.

Abstract

Background: Substantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality.

Methods: In this collaborative meta-analysis of general population cohorts, we pooled standardised data for all-cause and cardiovascular mortality from studies containing at least 1000 participants and baseline information about eGFR and urine albumin concentrations. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality associated with eGFR and albuminuria, adjusted for potential confounders.

Findings: The analysis included 105,872 participants (730,577 person-years) from 14 studies with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants (4,732,110 person-years) from seven studies with urine protein dipstick measurements. In studies with ACR measurements, risk of mortality was unrelated to eGFR between 75 mL/min/1.73 m(2) and 105 mL/min/1.73 m(2) and increased at lower eGFRs. Compared with eGFR 95 mL/min/1.73 m(2), adjusted HRs for all-cause mortality were 1.18 (95% CI 1.05-1.32) for eGFR 60 mL/min/1.73 m(2), 1.57 (1.39-1.78) for 45 mL/min/1.73 m(2), and 3.14 (2.39-4.13) for 15 mL/min/1.73 m(2). ACR was associated with risk of mortality linearly on the log-log scale without threshold effects. Compared with ACR 0.6 mg/mmol, adjusted HRs for all-cause mortality were 1.20 (1.15-1.26) for ACR 1.1 mg/mmol, 1.63 (1.50-1.77) for 3.4 mg/mmol, and 2.22 (1.97-2.51) for 33.9 mg/mmol. eGFR and ACR were multiplicatively associated with risk of mortality without evidence of interaction. Similar findings were recorded for cardiovascular mortality and in studies with dipstick measurements.

Interpretation: eGFR less than 60 mL/min/1.73 m(2) and ACR 1.1 mg/mmol (10 mg/g) or more are independent predictors of mortality risk in the general population. This study provides quantitative data for use of both kidney measures for risk assessment and definition and staging of chronic kidney disease.

Funding: Kidney Disease: Improving Global Outcomes (KDIGO), US National Kidney Foundation, and Dutch Kidney Foundation.

Copyright 2010 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow chart for selection of articles.

Figure 2

Figure 2

HRs and 95% CIs for all-cause and cardiovascular mortality according to spline eGFR and ACR adjusted for each other, age, gender, race, CVD history, systolic blood pressure, diabetes, smoking, and total cholesterol. The reference was eGFR 95 ml/min/1·73 m2 and ACR 5 mg/g (0·6 mg/mmol), respectively. Dots represent statistically significant and triangles represent not significant.

Figure 3

Figure 3

HRs and 95% CIs for all-cause and cardiovascular mortality according to spline eGFR and categorical albuminuria (ACR: <30 [black], 30-299 [green], and ≥300 [red] mg/g; dipstick: −/± [black], + [green], and ≥++ [red]) with their interaction terms adjusted for age, gender, race, CVD history, systolic blood pressure, diabetes, smoking, and total cholesterol. The reference was eGFR 95 ml/min/1·73 m2 plus ACR <30 mg/g or dipstick −/±. Dots represent statistically significant and triangles represent not significant. The estimated HR and 95% CI at eGFR 120 with dipstick ≥++ for CVD mortality were omitted, since only two studies contributed to reliable estimation. To convert ACR in mg/g to mg/mmol multiply 0.113.

Comment in

Similar articles

Cited by

References

    1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–59. - PubMed
    1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. - PubMed
    1. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–82. - PubMed
    1. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2003;14:S131–8. - PubMed
    1. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources